Biopharma Here to Stay: The Long-Term Case for the PBE ETF
January 20, 2021 at 10:25 AM EST
The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “is designed to provide capital appreciation by thoroughly evaluating companies based on a...